Aug 14
ENVB · Enveric Biosciences, Inc. · Documents
$1.52
+0.03 (+2.01%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from the issuance of these unaudited condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$6.80M
Shares
4.48M
Volume · Nov 12
32.25K
Avg daily vol (3M)
71.41K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2026
Aug 14
Quarterly report
10-Q
FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2
AI summary on its way
Net loss $3.03M
Diluted EPS -$0.76
Jun 9
Jun 9
May 29
Current report
8-K
Events of May 22
Director or officer change, or executive pay, Shareholder vote results
AI summary on its way
May 15
May 15
Quarterly report
10-Q
FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1
AI summary on its way
Net loss $1.63M
Diluted EPS -$1.08
Apr 30
Apr 30
Apr 23
Apr 20
Current report
8-K
Events of Apr 16
Entered into a material agreement, Unregistered sale of equity, Other events
AI summary on its way
Apr 14
Apr 14
Apr 14
Apr 3
Mar 27
Mar 27
Annual report
10-K
FY2025, ended Dec 31
Annual report for FY2025
AI summary on its way
Net loss $8.77M
Diluted EPS -$36.24
Feb 10
Feb 6
Jan 28
Current report
8-K
Events of Jan 27
Entered into a material agreement, Unregistered sale of equity
AI summary on its way
Jan 9
2025
Dec 22
Registration statement
S-3
Registration statement
Dec 12
Current report
8-K
Events of Dec 11
Entered into a material agreement, Unregistered sale of equity
Dec 11
Current report
8-K
Shareholder vote results
Dec 5
Registration statement
S-3/A
Registration statement
Nov 14
Current report
8-K
Financial results
Nov 14
Current report
8-K
Events of Nov 12
Other events
Nov 14
Quarterly report
10-Q
FY2025 Q3, ended Sep 30
Quarterly report for FY2025 Q3
Net loss $1.87M
Diluted EPS -$10.81
Oct 27
Proxy statement
DEF 14A
Proxy statement
Oct 23
Current report
8-K
Events of Oct 22
Delisting notice or listing transfer, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Other events
Oct 10
Proxy statement
PRE 14A
Proxy statement
Sep 29
Registration statement
S-3
Registration statement
Sep 18
Current report
8-K
Events of Sep 17
Entered into a material agreement, Unregistered sale of equity
Sep 2
Current report
8-K
Regulation FD disclosure, Other events
Aug 29
Current report
8-K
Events of Aug 26
Delisting notice or listing transfer
Aug 29
Current report
8-K
Regulation FD disclosure
Aug 14
Current report
8-K
Financial results
Aug 14
Quarterly report
10-Q
FY2025 Q2, ended Jun 30
Quarterly report for FY2025 Q2
Net loss $2.52M
Diluted EPS -$0.97
Jun 3
Current report
8-K
Events of May 29
Shareholder vote results
May 14
Current report
8-K
Financial results
May 14
Quarterly report
10-Q
FY2025 Q1, ended Mar 31
Quarterly report for FY2025 Q1
Net loss $2.18M
Diluted EPS -$1.22
Apr 16
Annual report to holders
ARS
Annual report to holders
Apr 15
Proxy statement
DEF 14A
Proxy statement
Apr 15
Proxy statement
DEFA14A
Proxy statement
Apr 14
Current report
8-K
Change of auditor
Apr 10
Registration statement
S-3/A
Registration statement
Apr 4
Proxy statement
PRE 14A
Proxy statement
Mar 31
Current report
8-K
Financial results
Mar 28
Annual report
10-K
FY2024, ended Dec 31
Annual report for FY2024
Net loss $9.57M
Diluted EPS -$19.04
Mar 6
Current report
8-K
Events of Mar 4
Other events
Showing 1–50 of 243 documents
Key facts
CIK
890821
CUSIP
29405E505
13F (30d)
16 filings
12 filers
Visit website
Investor relations